Journal article
Therapeutic opportunities: telomere maintenance in inducible pluripotent stem cells
Mutation research, Vol.730(1-2), pp.98-105
02/01/2012
DOI: 10.1016/j.mrfmmm.2011.05.008
PMCID: PMC3179558
PMID: 21605571
Abstract
It has been demonstrated that exogenous expression of a combination of transcription factors can reprogram differentiated cells such as fibroblasts and keratinocytes into what have been termed induced pluripotent stem (iPS) cells. These iPS cells are capable of differentiating into all the tissue lineages when placed in the right environment and, in the case of mouse cells, can generate chimeric mice and be transmitted through the germline. Safer and more efficient methods of reprogramming are rapidly being developed. Clearly, iPS cells present a number of exciting possibilities, including disease modeling and therapy. A major question is whether the nuclei of iPS cells are truly rejuvenated or whether they might retain some of the marks of aging from the cells from which they were derived. One measure of cellular aging is the telomere. In this regard, recent studies have demonstrated that telomeres in iPS cells may be rejuvenated. They are not only elongated by reactivated telomerase but they are also epigenetically modified to be similar but not identical to embryonic stem cells. Upon differentiation, the derivative cells turn down telomerase, the telomeres begin to shorten again, and the telomeres and the genome are returned to an epigenetic state that is similar to normal differentiated somatic cells. While these preliminary telomere findings are promising, the overall genomic integrity of reprogrammed cells may still be problematic and further studies are needed to examine the safety and feasibility of using iPS cells in regenerative medicine applications.
Details
- Title: Subtitle
- Therapeutic opportunities: telomere maintenance in inducible pluripotent stem cells
- Creators
- Francoise A Gourronc - Department of Microbiology, University of Iowa, IA, USAAloysius J Klingelhutz
- Resource Type
- Journal article
- Publication Details
- Mutation research, Vol.730(1-2), pp.98-105
- DOI
- 10.1016/j.mrfmmm.2011.05.008
- PMID
- 21605571
- PMCID
- PMC3179558
- NLM abbreviation
- Mutat Res
- ISSN
- 0027-5107
- eISSN
- 1873-135X
- Publisher
- Netherlands
- Grant note
- AG027388 / NIA NIH HHS R01 AG027388-05 / NIA NIH HHS R01 AG027388 / NIA NIH HHS
- Language
- English
- Date published
- 02/01/2012
- Academic Unit
- Microbiology and Immunology; Radiation Oncology
- Record Identifier
- 9984001132302771
Metrics
22 Record Views